Hongbo Deng

Hongbo Deng currently serves as Vice President of Medicinal Chemistry at General Oncology, a position held since June 2025. Prior to this role, Hongbo Deng was the Director of Medicinal Chemistry at Ensem Therapeutics from September 2021 to March 2025, where responsibilities included leading AI/ML-assisted oncology programs and managing collaborations with contract research organizations in China and the U.S. From October 2007 to September 2021, Hongbo Deng worked at Vertex Pharmaceuticals as a Senior Research Scientist, contributing to the development of VX-984 and VX-787, both significant candidates in their respective therapeutic areas. Earlier in the career, Hongbo Deng was a Scientist at Alantos Pharmaceuticals, where notable discoveries included potent inhibitors for osteoarthritis. Educational credentials include a Postdoctoral fellowship in Small Molecules from Boston College and a Ph.D. in Organic Synthesis from the University of California, Santa Cruz.